Who are we?


Signup for

Online registration

Log in to register
your trial

Search a trial




van CCT (UK)

van CCT (UK)

“Pre-operatieve Iron” use as blood sparing technique in Orthopedic Surgery (THP en TKP surgery, elective and no revision surgery).

- candidate number14043
- NTR NumberNTR3731
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR30-nov-2012
- Secondary IDsNL35394.101.11 CCMO
- Public Title“Pre-operatieve Iron” use as blood sparing technique in Orthopedic Surgery (THP en TKP surgery, elective and no revision surgery).
- Scientific Title“Pre-operatieve Iron” use as blood sparing technique in Orthopedic Surgery (THP en TKP surgery, elective and no revision surgery).
- ACRONYMPOP-i study
- hypothesisIn this research we will investigate if i.v. iron therapy can become a method of blood saving therapy for orthopedic surgery and can replace erytropoietin.
- Healt Condition(s) or Problem(s) studiedOrthopedic surgery, Total hip replacement, Total knee arthroplasty, Parenteral iron, Epo
- Inclusion criteriaOrthopedic patients planned for primary Total Hip and total Knee replacement operations with an preoperative Hb > 6,1 and ≤ 8,1 mmol/l.
- Exclusion criteria1. Revision operations;
2. Preop Hb <= 6,1 mmol/l or > 8,2 mmol/l;
3. All patients who wish not to receive blood transfusions;
4. Uncontrolled hypertension (Diastolic blood pressure > 95 mm Hg);
5. Patients planned for preoperative autologous donation, cell salvage, wound reinfusion;
6. Severe cardiac compromised patients, uncontrolled hypertension, severe disease periferal arteries, art carotis or art cerebralis;
7. Recent myocardial infarction of CVA or instable angina pectoris or heart failure;
8. Prone for trombosis (f.i. Factor V Leiden);
9. All patients with Hb-globinopathy such as sickle cell anemia or thalassemia;
10. Patients with oncological processes except curred malignancy or skin cancer;
11. Pregnancy;
12. Patients with ciclosporin therapy;
13. Unpossible to give prophylactic anticoagulant;
14. Allergy Epo or i.v. iron or additives;
15. Infected wound, infected prothesis, infectious process at the moment of inclusion;
16. Epileptic, chronic kidney and liver insufficiency;
17. Iron diseases.
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingTriple
- controlNot applicable
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-jan-2013
- planned closingdate1-jan-2015
- Target number of participants1020
- InterventionsThree-arm randomised study in patients with a start Hb level > 6,1 and < = 8,1 mmol/l.

Intervention groups will be compared with a control group.
The intervention group will receive i.v. iron infusion or Epo.
The control group will receive no intervention. Both groups will be transfused following the Dutch Transfusion Guideline (4,5,6, Flexinorm).
- Primary outcomeCan ferric carboxymaltose effectively reduce RBC transfusion rate compared to controles in elective orthopaedic surgery patients?

Primary endpoints: Rate of transfused patients.
- Secondary outcome1. Is i.v. iron therapy increase preoperative Hb-levels and improve postoperative recovery;
2. Is this i.v. iron therapy also efficient for patients with anemia other than iron deficiency (ACD);
3. Is infusion of i.v. iron policlinically safe?;
4. Cost reductions caused by introduction of i.v. iron therapy (can it then replace Epo?).

Secundary endpoints:
Hospital stay, postoperative complications, time needed for revalidation, measurement of quality of life, total cost treatment, Hb-levels preo- and postoperatively, amount of RBC per patient, safety of IV iron.
- Timepoints3 months follow up.
- Trial web siteN/A
- statusplanned
- CONTACT for SCIENTIFIC QUERIESDr. W.M.M. Koopman-van Gemert
- Sponsor/Initiator Albert Schweitzer Ziekenhuis
- Funding
(Source(s) of Monetary or Material Support)
Albert Schweitzer Ziekenhuis, Dordrecht
- PublicationsN/A
- Brief summaryInvestigated are patients planned for a primary, elective total hip or total knee replacement operation. Patients with a Hb > 6,1 and ≤ 8,1 mmol/l, measured 2 weeks before visit to the preoperative poli of the anesthesiologist, will be included. It will be a three arm, Randomized Controlled trial. Patients in the IV iron intervention group will receive 1 gr i.v. iron on the day care at the day of the visit. Patients in the Epo group will receive 4 weekly injections of 40.000 I.U. of Epo, supported bij oral iron therapy. In the control group patients will receive standard care. In case of measured iron deficiency, patient willen receive oral iron therapy. Al patients will be operated 4 weeks after start of therapy.
Both groups will be transfused following the CBO guideline Blood Transfusion 2011, (4,5,6, Flexinorm).
- Main changes (audit trail)
- RECORD30-nov-2012 - 16-dec-2012

  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar